The objective of this pilot trial was to evaluate the safety and efficacy of AKL1 , a patented botanical formulation containing extracts of Picrorhiza kurroa , Ginkgo biloba , and Zingiber officinale , as add-on therapy for patients with chronic obstructive pulmonary disease ( COPD ) and chronic cough .